77.62
price up icon2.27%   1.72
after-market After Hours: 77.61 -0.01 -0.01%
loading
Bio Techne Corp stock is traded at $77.62, with a volume of 530.73K. It is up +2.27% in the last 24 hours and up +3.80% over the past month. Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. It reports in two segments: protein sciences (75% of revenue) and diagnostics and genomics (25%). The protein sciences segment sells reagents and analytical instruments used in life sciences research, including antibodies used in protein analysis. The diagnostics and genomics segment sells diagnostic reagents, molecular diagnostics, and spatial biology products. The United States accounts for about 55% of revenue. The firm also has operations in Europe, the Middle East, and Africa (20% of sales), the UK (5%), and Asia-Pacific (15%), with the rest of the world accounting for the remaining 5%.
See More
Previous Close:
$75.90
Open:
$74.91
24h Volume:
530.73K
Relative Volume:
0.61
Market Cap:
$12.31B
Revenue:
$1.16B
Net Income/Loss:
$168.11M
P/E Ratio:
51.07
EPS:
1.52
Net Cash Flow:
$236.10M
1W Performance:
+9.73%
1M Performance:
+3.80%
6M Performance:
+0.43%
1Y Performance:
+32.19%
1-Day Range:
Value
$73.92
$77.65
1-Week Range:
Value
$73.75
$79.46
52-Week Range:
Value
$55.63
$85.57

Bio Techne Corp Stock (TECH) Company Profile

Name
Name
Bio Techne Corp
Name
Phone
(612) 379-8854
Name
Address
614 MCKINLEY PL N E, MINNEAPOLIS, MN
Name
Employee
3,100
Name
Twitter
@biotechne
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
TECH's Discussions on Twitter

Bio Techne Corp Stock (TECH) Upgrades & Downgrades

Date Action Analyst Rating Change
May-22-24 Downgrade Citigroup Buy → Neutral
Feb-08-24 Initiated Scotiabank Sector Outperform
Feb-02-24 Downgrade Stifel Buy → Hold
Dec-07-23 Initiated UBS Buy
Aug-28-23 Initiated William Blair Outperform
Jan-10-23 Upgrade Wells Fargo Underweight → Equal Weight
Dec-14-22 Initiated Deutsche Bank Buy
Dec-12-22 Upgrade Citigroup Neutral → Buy
Dec-07-22 Initiated RBC Capital Mkts Sector Perform
Aug-25-22 Initiated Credit Suisse Outperform
Apr-25-22 Downgrade Wells Fargo Equal Weight → Underweight
Sep-15-21 Upgrade KeyBanc Capital Markets Sector Weight → Overweight
Mar-08-21 Upgrade Stephens Equal-Weight → Overweight
Feb-23-21 Upgrade Stifel Hold → Buy
Jan-25-21 Reiterated The Benchmark Company Buy
Nov-10-20 Initiated KeyBanc Capital Markets Sector Weight
Sep-30-20 Initiated Atlantic Equities Overweight
Jul-15-20 Downgrade Stephens Overweight → Equal-Weight
May-27-20 Downgrade Stifel Buy → Hold
May-14-20 Initiated The Benchmark Company Buy
Jan-08-20 Resumed Stephens Overweight
Jan-08-20 Initiated Wells Fargo Equal Weight
Jan-07-20 Initiated Citigroup Neutral
Nov-15-19 Initiated Stifel Buy
Jul-02-19 Upgrade Janney Neutral → Buy
Jan-14-19 Upgrade Stephens Equal-Weight → Overweight
Oct-31-18 Downgrade Craig Hallum Buy → Hold
Oct-17-18 Initiated Goldman Neutral
Jun-15-18 Initiated Argus Buy
Jul-13-17 Initiated Wells Fargo Market Perform
Feb-09-17 Initiated Citigroup Buy
Jan-18-17 Initiated Deutsche Bank Buy
Nov-10-16 Resumed Leerink Partners Outperform
Jan-21-15 Reiterated Robert W. Baird Outperform
Sep-20-13 Upgrade Robert W. Baird Neutral → Outperform
View All

Bio Techne Corp Stock (TECH) Latest News

pulisher
05:25 AM

Bio-Techne awards CFO restricted stock units for retention - Investing.com

05:25 AM
pulisher
07:00 AM

LUNAPHORE COMET™ PLATFORM PAVES THE WAY FOR SPATIAL BIOLOGY ADOPTION IN CLINICAL RESEARCH - Yahoo Finance

07:00 AM
pulisher
04:49 AM

Bio-Techne Co. (NASDAQ:TECH) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat

04:49 AM
pulisher
Nov 04, 2024

Bio-Techne Tops Q1 Earnings & Revenue Estimates, Stock Up in Premarket - MSN

Nov 04, 2024
pulisher
Nov 04, 2024

Bio-Techne Corp (TECH)'s Winning Formula: Financial Metrics and Competitive Strengths - GuruFocus.com

Nov 04, 2024
pulisher
Nov 03, 2024

New York State Common Retirement Fund Reduces Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Nov 03, 2024
pulisher
Nov 03, 2024

Bio-Techne (NASDAQ:TECH) Raised to Buy at StockNews.com - Defense World

Nov 03, 2024
pulisher
Nov 02, 2024

Bio-Techne (NASDAQ:TECH) Upgraded to Buy at StockNews.com - MarketBeat

Nov 02, 2024
pulisher
Nov 01, 2024

9 Best Biotech Stocks Of November 2024 - Forbes

Nov 01, 2024
pulisher
Nov 01, 2024

Bio-Techne Corporation (NASDAQ:TECH) Q1 2025 Earnings Call Transcript - Insider Monkey

Nov 01, 2024
pulisher
Oct 31, 2024

TECH (Bio-Techne) Total Inventories : $185 Mil (As of Sep. 2024) - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Bio-Techne shares target raised, outperform on strong Q1 results By Investing.com - Investing.com Australia

Oct 31, 2024
pulisher
Oct 31, 2024

Earnings call: Bio-Techne reports steady growth in Q1 FY2025 - Investing.com

Oct 31, 2024
pulisher
Oct 31, 2024

Earnings call: Bio-Techne reports steady growth in Q1 FY2025 By Investing.com - Investing.com UK

Oct 31, 2024
pulisher
Oct 31, 2024

Bio-Techne shares target raised, outperform on strong Q1 results - Investing.com India

Oct 31, 2024
pulisher
Oct 31, 2024

Robert W. Baird Forecasts Strong Price Appreciation for Bio-Techne (NASDAQ:TECH) Stock - MarketBeat

Oct 31, 2024
pulisher
Oct 31, 2024

Bio-Techne Corp (TECH) Q1 2025 Earnings Call Highlights: Navigat - GuruFocus.com

Oct 31, 2024
pulisher
Oct 31, 2024

Bio-Techne Corp (TECH) Q1 2025 Earnings Call Highlights: Navigating Growth and Challenges in a ... - Yahoo Finance

Oct 31, 2024
pulisher
Oct 30, 2024

Bio-Techne holds at $80 target with Overweight rating - Investing.com India

Oct 30, 2024
pulisher
Oct 30, 2024

Bio-Techne holds at $80 target with Overweight rating By Investing.com - Investing.com South Africa

Oct 30, 2024
pulisher
Oct 30, 2024

Objective long/short (TECH) Report - Stock Traders Daily

Oct 30, 2024
pulisher
Oct 30, 2024

Bio-Techne Tops Profit Forecasts Thanks To Booming Diagnostics - Finimize

Oct 30, 2024
pulisher
Oct 30, 2024

Bio-Techne Q1 25 Earnings Conference Call At 9:00 AM ET - Nasdaq

Oct 30, 2024
pulisher
Oct 30, 2024

Bio-Techne beats quarterly profit estimates, driven by diagnostic unit growth; shares rise - Reuters

Oct 30, 2024
pulisher
Oct 30, 2024

Bio-Techne Corp (TECH) Q1 FY2025 Earnings: Revenue Surpasses Est - GuruFocus.com

Oct 30, 2024
pulisher
Oct 30, 2024

Bio-Techne earnings beat by $0.04, revenue topped estimates - Investing.com

Oct 30, 2024
pulisher
Oct 30, 2024

BIO-TECHNE RELEASES FIRST QUARTER FISCAL 2025 RESULTS - Yahoo Finance

Oct 30, 2024
pulisher
Oct 30, 2024

Bio-Techne Co. (NASDAQ:TECH) Shares Sold by Creative Planning - MarketBeat

Oct 30, 2024
pulisher
Oct 30, 2024

Sequoia Financial Advisors LLC Purchases Shares of 2,725 Bio-Techne Co. (NASDAQ:TECH) - Defense World

Oct 30, 2024
pulisher
Oct 29, 2024

Global Exosome Market to Surge at a Tremendous CAGR of ~20% by 2030 | DelveInsight - GlobeNewswire Inc.

Oct 29, 2024
pulisher
Oct 29, 2024

ScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics - Yahoo Finance

Oct 29, 2024
pulisher
Oct 28, 2024

Director Keegan Joseph D was granted 1,462 shares, increasing direct ownership by 12% to 13,771 units (SEC Form 4) - Quantisnow

Oct 28, 2024
pulisher
Oct 28, 2024

IFM Investors Pty Ltd Boosts Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Oct 28, 2024
pulisher
Oct 26, 2024

Bio-Techne Gears Up for Q1 Earnings Release: What's in the Cards? - MSN

Oct 26, 2024
pulisher
Oct 25, 2024

Hahn Capital Management LLC Reduces Stock Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Oct 25, 2024
pulisher
Oct 24, 2024

Raymond James & Associates Boosts Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Oct 24, 2024
pulisher
Oct 23, 2024

Bio-Techne, Ex-Lead Scientist Settle Religious Bias Claim (1) - Bloomberg Law

Oct 23, 2024
pulisher
Oct 23, 2024

Bio-Techne (TECH) Scheduled to Post Earnings on Wednesday - MarketBeat

Oct 23, 2024
pulisher
Oct 22, 2024

Allspring Global Investments Holdings LLC Decreases Holdings in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Oct 22, 2024
pulisher
Oct 21, 2024

CRISPR-based Gene Editing Market Report 2024-2030, Featuring Revvity, Danaher, GenScript, Merck, Tocris Bioscience, OriGene Technologies, Bio-Rad Laboratories, Bio-Techne & New England Biolabs - Yahoo Finance

Oct 21, 2024
pulisher
Oct 21, 2024

S&P 500 Futures Fall in Premarket Trading; Kenvue, Bio-Techne Lead - Barron's

Oct 21, 2024
pulisher
Oct 19, 2024

When the Price of (TECH) Talks, People Listen - Stock Traders Daily

Oct 19, 2024
pulisher
Oct 16, 2024

What You Need To Know Ahead Of Bio-Techne's Earnings Release - Barchart

Oct 16, 2024
pulisher
Oct 16, 2024

What You Need to Know Ahead of Bio-Techne's Earnings Release - Inkl

Oct 16, 2024
pulisher
Oct 16, 2024

Sanctuary Advisors LLC Takes Position in Bio-Techne Co. (NASDAQ:TECH) - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Transferrin Monoclonal Antibody Market 2034 Insights with Key Innovations Analysis |MyBiosource, Inc., Bio-Techne, ​​Abc – IndiaPolitics.com - IndiaPolitics.com

Oct 15, 2024
pulisher
Oct 14, 2024

Anti-Olig2 Antibody Market Year 2034|Sino Biological, Inc., Boster Biological Technology, Bio-Techne, Thermo Fisher, CLO – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 14, 2024

CD30 (TNFRSF8) ELISA Kit Market Growth Report |Sino Biological, Inc., Bio-Techne, MyBiosource, Inc., Boster Biological T – IndiaPolitics.com - IndiaPolitics.com

Oct 14, 2024
pulisher
Oct 14, 2024

An Analysis of Bio-Techne Corp (TECH)’s Potential Price Growth - Knox Daily

Oct 14, 2024
pulisher
Oct 14, 2024

Investors in cash trouble should check out Bio-Techne Corp (TECH) - SETE News

Oct 14, 2024
pulisher
Oct 11, 2024

Bio-Techne Co. (NASDAQ:TECH) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat

Oct 11, 2024

Bio Techne Corp Stock (TECH) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Bio Techne Corp Stock (TECH) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Kelderman Kim
Chief Executive Officer
Aug 29 '24
Option Exercise
66.97
1,492
99,919
41,434
Bohnen Shane
SVP - General Counsel
Aug 15 '24
Option Exercise
0.00
49
0
1,696
BAUMGARTNER ROBERT V
Director
Aug 08 '24
Option Exercise
22.95
16,000
367,200
59,401
BAUMGARTNER ROBERT V
Director
Aug 08 '24
Sale
72.10
16,000
1,153,664
43,401
$77.28
price up icon 2.02%
$20.39
price up icon 2.15%
$382.77
price up icon 1.58%
$53.29
price down icon 0.47%
$208.03
price up icon 0.38%
$110.97
price up icon 1.84%
Cap:     |  Volume (24h):